

A GLOBAL PHARMACEUTICAL COMPANY

Pluvia Pharmaceutical Investment, founded in 2022 as the umbrella organization of Pluvia Pharma, Pluvia Consumer Health and Pluvia Apisyntech, which brings together a wealth of experience and expertise to build a strong foundation in healthcare, is a global pharmaceutical company dedicated to improving the health of people around the world.





Pluvia Consumer Health

Pluvia Consumer Health Co. is a multinational pharmaceutical company with its headquarter located in Istanbul, Turkey with unique molecules & Know-How. Our portfolio contains several specific APIs & Finished Dosage form medications in the field of various therapeutic categories (NSAIDs, metabolic syndrome, hematology, GLS, central nervous system, urogenital, antineoplastic, antiviral) as well as Opioid medications & Nutraceutical Supplements.

Since Manufacturing/Procurement of our products are being done by ourselves and based on our own specific Know-How from A to Z, therefore, we are able to support you in documentation, formulation & scientific matters, in addition to supplying you with unique quality products at unrivaled prices (including different types of APIs & Finished dosage Forms).



Why Choosing Pluvia Consumer Health

Enhancement of your portfolio with a unique and wide range product categories along with providing you with relevant CTDs.

- Supplying you with a high quality Active Ingredients
- Granting you an Under License manufacturing right by a EUROPEAN company
- Flexible Payment Terms
- Connecting to a Flexible & Agile R&D for development
- Our R&D infrastructure supports advanced research and innovation, and our team is dedicated to the development of new drug applications and innovations through knowledge-based researches.









BUPRENORPHINE

Buprenorphine 0.4mg	Box (100 tablets)	Sublingual Tablet			
Buprenorphine 2mg	Box (100 tablets)	Sublingual Tablet			
Buprenorphine 8mg	Box (100 tablets)	Sublingual Tablet			

used for the treatment of severe pain and also commonly used for the treatment of severe opioid addiction.

Therapeutic Fields

- Maintenance treatment of moderate to severe opioid use disorder
- Management of pain severe enough to require around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Active Substance

Buprenorphine 0.4 mg/ 2 mg/8 mg









BUPRENORPHINE NALOXONE

Buprenorphine - Naloxone 2 mg /0.5mg	Box (100 tablets)	Sublingual Tablet
Buprenorphine - Naloxone8 mg /2mg	Box (100 tablets)	Sublingual Tablet

Buprenorphine/Naloxone Sublingual tablet contains buprenorphine, a partial-opioid agonist, and naloxone, an opioid antagonist.

Therapeutic Fields


Buprenorphine/Naloxone is indicated for the treatment of opioid dependence.

It should be used as part of a complete treatment plan to include counseling and psychosocial support.

Active Substance

Buprenorphine 2 mg - Naloxone 0.5 mg

Buprenorphine 8 mg - Naloxone 2mg







METHADONE

Methadone 5 mg	Box (100 tablets)	Tablet			
Methadone 20 mg	Box (100 tablets)				
Methadone 40 mg	Box (100 tablets)	Tablet			
Methadone 25mg - 5ml	Bottle 250ml	Syrup			

Methadone hydrochloride is a mu-agonist; a synthetic opioid with multiple actions qualitatively similar to those of morphine, the most prominent of which involves the central nervous system and organs composed of smooth muscle.

Therapeutic Fields

- Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
- Detoxification treatment of opioid addiction (heroin or other morphine-like drugs).

Active Substance

Methadone Tablet 5mg /20mg/40mg Methadone Oral Solution 25mg/5ml





NALTREXONE

Naltrexone is a medication primarily used to manage alcohol or opioid use disorder by reducing cravings and feelings of euphoria . It has also been found to be effective in the treatment of other addictions and may be used for them off-label.

Therapeutic Fields

- To treat alcohol dependence
- For the blockade of the effects of exogenously administered opioids. To prevent relapse to opioid dependence, after opioid detoxification

Ingredients

Naltrexone





ACETAMINOPHEN (PARACETAMOL)

CODEINE 300mg/20mg

Acetaminophen (Paracetamol) codeine 300mg/20mg	Box (100 tablets)	Scored Tablet
--	-------------------	---------------

A compound analgesic consisting a combination of Acetaminophen and Codeine phosphate.

Therapeutic Fields

Management of mild to moderate pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate.

Active Substance

Acetaminophen 300mg Codeine 20mg





FAROXY OXYCODONE IR

Oxycodone IR 5 mg	Box (30 tablets)	Film Coated Tablet			
Oxycodone IR 15 mg	Box (30 tablets)	Film Coated Tablet			
Oxycodone IR 30 mg	Box (30 tablets)	Film Coated Tablet			

Oxycodone is a semisynthetic opiate partial agonist derived from the opioid alkaloid, Thebaine.

Therapeutic Fields

Fast Relief of Acute Pain

Active Substance

Oxycodone Immediate-release Tablet 5, 15 & 30mg





FAROXY ER OXYCODONE ER

Oxycodone ER 10 mg	Box (60 tablets)	Film Coated Tablet				
Oxycodone ER 20 mg	Box (60 tablets)					
Oxycodone ER 40 mg	Box (60 tablets)	Film Coated Tablet				

Oxycodone is a semisynthetic opiate partial agonist derived from the opioid alkaloid, Thebaine.

Therapeutic Fields

Long Term Opioid Therapy

- Chronic pain relief
- For long term opioid therapy

Active Substance

Oxycodone Extended-release Tablet 10, 20 & 40mg









FAROXYPHEN

ACETAMINOPHEN - OXYCODONE

Acetaminophen - Oxycodone 325mg / 5 mg	Box (30 tablets)	Scored Tablet
Acetaminophen - Oxycodone 325mg / 10 mg	Box (30 tablets)	Scored Tablet

Oxycodone is a semisynthetic opiate partial agonist derived from the opioid alkaloid, Thebaine.

Therapeutic Fields

Effective Combination for Add-on Therapy and Rescue Dose

- As an adjuvant therapy if necessary
- As a rescue dose for Break Through Pain (BTP)

Active Substance

Acetaminophen 325 mg and Oxycodone 5 / 10 mg







ACTIVE INGREDIENTS (API)

Controlled Substance / Narcotic

Product Name	CAS. No	USP (United States Pharmacopeia)	BP (British Pharmacopoeia)	ChP (Chinese Pharmacopoeia, also known as PPRC)	In house method	GMP	COA	DMF	MSDS	SMF	PIC/S Written Confirmation
Codeine Phosphate Hemihydrate	41444-62-6	\checkmark									
Buprenorphine HCl	53152-21-9	\checkmark	\checkmark			<u> </u>	\checkmark				
Oxycodone HCl	124-90-3		\checkmark			<u> </u>	\checkmark				
Methadone HCl	1095-90-5		\checkmark						<u> </u>		\checkmark
Morphine Sulfate	6211-15-0		<u> </u>					<u> </u>	<u> </u>	<u> </u>	\checkmark
N-Methylnorbuprenorphine 3-Methyl Ether	16196-70-6	<u> </u>	\checkmark			<u> </u>					
Opium Tincture	NA				\checkmark				<u> </u>		\checkmark



ACTIVE INGREDIENTS (API)

Non-Controlled Substance / Non-Narcotic

Product Name	CAS. No	USP (United States Pharmacopeia)	BP (British Pharmacopoeia)	ChP (Chinese Pharmacopoeia, also known as PPRC)	In house method	GMP	COA	DMF	MSDS	SMF	PIC/S Written Confirmation
Noscapine Base	128-62-1		<u> </u>	\checkmark		<u> </u>	<u></u>	<u></u>	<u></u>	<u> </u>	$\overline{\checkmark}$
Papaverine HCI	58-74-2	\checkmark	\checkmark			<u></u>	<u></u>	<u></u>	<u></u>	<u></u>	\checkmark
Naloxone HCl	51481-60-8		<u> </u>			<u> </u>	<u> </u>	<u></u>	<u></u>	<u> </u>	\checkmark
Naltrexone HCl	16590-41-3	\checkmark	\checkmark			<u> </u>	<u></u>	<u></u>	<u></u>	<u></u>	\checkmark
Tramadol HCl	36282-47-0	<u> </u>	\checkmark				<u></u>			<u></u>	
Methyl nalbuphine	90242-27-6	<u> </u>	\checkmark							<u></u>	
Nalbuphine	20594-83-6	<u> </u>	\checkmark							<u></u>	
Noroxymorphone	33522-95-1	<u> </u>	\checkmark			<u></u>	<u></u>			<u></u>	
Noroxymorphone HCl	52446-24-9	<u> </u>	<u> </u>			<u></u>	<u></u>			<u></u>	
Naloxone methyl ether	131830-09-6	<u> </u>	\checkmark			<u> </u>	<u></u>			<u></u>	
Sitagliptin phosphate	654671-77-9	<u> </u>	\checkmark			<u> </u>	<u></u>			<u></u>	
Linagliptin	668270-12-0				<u> </u>	<u> </u>	<u> </u>			/	
Empagliflozin	864070-44-0				<u> </u>	<u> </u>	<u></u>			<u> </u>	\checkmark
Apixaban	503612-47-3				<u> </u>	_	_	<u></u>	<u></u>	/	
Pregabalin	148553-50-8	\checkmark	<u> </u>			<u></u>	<u></u>	<u></u>		<u></u>	\checkmark



PARTNERSHIP

Partnership Models with Pluvia Consumer Health

1- Joint Venture

This model is one of the most powerful tools for being successful in today's competitive business atmosphere. Even the joint venture can create a separate business entity, to which the owners contribute assets, have equity, and agree on how this entity may be managed. The new entity may be a corporation, limited liability company, or partnership. Main advantages of this model is capturing an eye-catching market share along with income through leveraging the market by using abilities & relationships of the host company from the first entrance stage with the lowest risk & cost.

2- Strategic Alliance

Setting up a formal relationship & cooperation between two parties to meet a critical business need & make a synergy with maintaining both parties' independency. Each partner hopes that the benefits from the alliance will be greater than those from individual efforts. Main characteristics:

- High level of transparency between partners
- Common long-term strategy and goals
- Pooling/sharing ideas
- Increased business opportunities and reach



3- Franchise & licensing

1- License-In

Under license manufacturing of specific drugs' dossiers with the aim of own portfolio enhancement.

2- License-Out

We are working to expand our global strategic marketing partnerships for products developed-in house. In this regard, we are ready to grant our Know-How, Experts & Expertise.

4- Distribution Agreement

Mutual Co-operation in regard with Sales & Distribution of parties' products in order to market expansion.

We are ready to make a distribution contract with well-known international companies with an interesting & valuable portfolio. Vice-versa, we are looking for a strong international distributor or wholesaler who is authorized for working on our products.

5- Contract Manufacturing

When you choose us for Contract Manufacturing, you get so much more than a typical CMO engagement. Through the partnership, you gain integrated access to scientific expertise, High quality & unrivaled rates.



SPECIAL OFFER from Pluvia Consumer Health

- Providing CTD/ FORMULLA for FDFs
- European Out-Licensing
- API Supply
- Manufacturing and Procurement Products with Your Own Label
- Technical & Scientific Supports
- Flexible Payment Terms
- GMP CEP PIC/S Written Confirmation





Pluvia Consumer Health is subsidiary of Pluvia Pharmaceutical Investment



- Address: Maslak, VEKO GIZ PLAZA, 1st floor, Pluvia Consumer Health
- Phone: +90 545 918 35 85/ +90 5396161559
- © **Tel:** +90 2122904030 (Ext.: 114)
- Email: export.endo@pluviaglobal.com / info@pluviaglobal.com
- Website: www.pluviaendo.com